Nektar Therapeutics opened lower at $38.32, compared with its previous close of $38.44. In the last trading session, the stock traded between $37.01 and $38.32. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Nektar Therapeutics is now worth
$ 18.35
Resulting in a loss of
$ 81.65 (81.65%)
Invest with $1
Note: Past profits do not guarantee future returns.
Loss per share narrowed to $1.63, beating the $2.08 analyst estimate by 21.63%. Quarterly revenue fell 20.39% YoY to $9.386 million, missing estimates by 8.64%. Cash and investments held at $952.9 million. Loss per share improved 12.83% from $(1.87) in the prior-year quarter.
Today
1Oct
Nektar presents rezpegaldesleukin Phase 2b data at EADV Congress
Nektar Therapeutics presents long-term data on rezpegaldesleukin at EADV Congress 2026. Data covers Phase 2b REZOLVE-AA and REZOLVE-AD trials. Presentations scheduled as oral sessions in Vienna, Austria.
1mo ago
25Sep
Jury awards Nektar Therapeutics $90M in damages against Eli Lilly
Jury found Eli Lilly breached implied covenant of good faith. Nektar Therapeutics awarded $90 million in damages. Interest amount to be determined by District Court. Verdict subject to post-trial proceedings and potential appeal.
1mo ago
16Sep
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Target
BTIG analyst Julian Harrison reiterates a Buy rating on Nektar Therapeutics (NASDAQ: NKTR). The firm maintains its previous price target of $178 for the stock. No changes were made to the rating or target in this update.
1mo ago
9Sep
Nektar Therapeutics enters quiet period ahead of Phase 2b alopecia data
Nektar Therapeutics enters a quiet period starting September 8. The pause lasts until the public announcement of Phase 2b REZOLVE-AA study data. Data covers the 24-week off-treatment follow-up for alopecia areata patients. Rezpegaldesleukin is the drug candidate under evaluation in the trial.
2mo ago
25Aug
Nektar Therapeutics publishes positive Phase 2b atopic dermatitis data
Nektar Therapeutics published Phase 2b REZOLVE-AD data in The Lancet. Rezpegaldesleukin met all primary and key secondary endpoints. Trial evaluated 24 µg/kg q2w dosage over 16-week induction period. Findings support ongoing Phase 3 ZENITH AD clinical program development.
